Boehringer Ingelheim Signs Agreement With Hokkaido-Based Evec
This article was originally published in PharmAsia News
Executive Summary
Major pharmaceutical company Boehringer Ingelheim of Germany signed a license agreement with Evec, a Hokkaido University-based biopharmaceutical venture company. According to the agreement, BI obtains worldwide exclusive rights on development and marketing for one of Evec's human therapeutic antibody programs. In return, Evec could receive up to €55 million in upfront and potential milestone payments. Evec will also receive royalties after the product's market launch. Established in 2003 and based in Sapporo, Hokkaido, Evec utilizes Epstein-Barr virus' lymphoproliferative. (Click here for more - Japanese language
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.